GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicamen Organics Ltd (NSE:MEDIORG) » Definitions » ROE %

Medicamen Organics (NSE:MEDIORG) ROE % : 16.49% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Medicamen Organics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Medicamen Organics's annualized net income for the quarter that ended in Mar. 2024 was ₹22.3 Mil. Medicamen Organics's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was ₹135.0 Mil. Therefore, Medicamen Organics's annualized ROE % for the quarter that ended in Mar. 2024 was 16.49%.

The historical rank and industry rank for Medicamen Organics's ROE % or its related term are showing as below:

NSE:MEDIORG' s ROE % Range Over the Past 10 Years
Min: 1.31   Med: 7.7   Max: 20.05
Current: 20.05

During the past 4 years, Medicamen Organics's highest ROE % was 20.05%. The lowest was 1.31%. And the median was 7.70%.

NSE:MEDIORG's ROE % is ranked better than
89.23% of 966 companies
in the Drug Manufacturers industry
Industry Median: 4.485 vs NSE:MEDIORG: 20.05

Medicamen Organics ROE % Historical Data

The historical data trend for Medicamen Organics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicamen Organics ROE % Chart

Medicamen Organics Annual Data
Trend Mar21 Mar22 Mar23 Mar24
ROE %
3.99 1.31 11.41 19.90

Medicamen Organics Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24
ROE % - - - 24.84 16.49

Competitive Comparison of Medicamen Organics's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicamen Organics's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's ROE % distribution charts can be found below:

* The bar in red indicates where Medicamen Organics's ROE % falls into.



Medicamen Organics ROE % Calculation

Medicamen Organics's annualized ROE % for the fiscal year that ended in Mar. 2024 is calculated as

ROE %=Net Income (A: Mar. 2024 )/( (Total Stockholders Equity (A: Mar. 2023 )+Total Stockholders Equity (A: Mar. 2024 ))/ count )
=24.041/( (89.799+151.84)/ 2 )
=24.041/120.8195
=19.90 %

Medicamen Organics's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=22.26/( (118.083+151.84)/ 2 )
=22.26/134.9615
=16.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Medicamen Organics  (NSE:MEDIORG) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=22.26/134.9615
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(22.26 / 279.034)*(279.034 / 365.4475)*(365.4475 / 134.9615)
=Net Margin %*Asset Turnover*Equity Multiplier
=7.98 %*0.7635*2.7078
=ROA %*Equity Multiplier
=6.09 %*2.7078
=16.49 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=22.26/134.9615
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (22.26 / 32.748) * (32.748 / 41.21) * (41.21 / 279.034) * (279.034 / 365.4475) * (365.4475 / 134.9615)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6797 * 0.7947 * 14.77 % * 0.7635 * 2.7078
=16.49 %

Note: The net income data used here is two times the semi-annual (Mar. 2024) net income data. The Revenue data used here is two times the semi-annual (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Medicamen Organics ROE % Related Terms

Thank you for viewing the detailed overview of Medicamen Organics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicamen Organics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ashok Vihar Phase II, 10, Community Center No. 2, New Delhi, IND, 110052
Medicamen Organics Ltd is engaged in developing, manufacturing, and distribution of broad range of pharmaceutical dosages including generic dosages in the form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government and private institutions as contract manufacturer/third party manufacturer. The company markets its product to private pharma companies in domestic as well as international markets through third-party distributors or on a loan license basis.

Medicamen Organics Headlines

No Headlines